stockportfolio.pro
Stocks / BIIB vs RPRX
BIIB vs RPRX
Biogen Inc. and Royalty Pharma plc side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
RPRX is the larger company ($31.6B vs $29.3B). On the fundamentals, RPRX grows revenue faster (2.3% vs -6.0%); RPRX earns a higher net margin (32.4% vs 13.1%); RPRX has the stronger return on equity (11.9% vs 7.1%). Full numbers below — the stronger figure on each row is in green.
| Biogen Inc. (BIIB) | Royalty Pharma plc (RPRX) | |
|---|---|---|
| Market cap | $29.3B | $31.6B |
| Revenue (latest FY) | $9.89B | $2.38B |
| Net income (latest FY) | $1.29B | $770.95M |
| Revenue growth (5y CAGR) | -6.0% | 2.3% |
| Net margin | 13.1% | 32.4% |
| Return on equity | 7.1% | 11.9% |
| P/E ratio | 21.4 | 28.9 |
| Dividend yield | — | 1.7% |
| Profitable years (of last 10) | 10 | 8 |
| Positive free cash flow | Yes | — |
Compare with another company:
See the full BIIB vs RPRX breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open BIIB's full financials → Open RPRX's full financials →More comparisons
Frequently asked questions
Which is bigger, BIIB or RPRX?
Royalty Pharma plc is larger by market capitalization — $31.6B versus $29.3B.
Which grows faster, BIIB or RPRX?
Over the last five fiscal years, Royalty Pharma plc grew revenue faster — 2.3%/yr versus -6.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
BIIB fundamentals → · RPRX fundamentals → · All 1,500+ companies → · Free screener →